The corresponding number of mapped genes
had risen to 928 by the ninth meeting in 1987 as molecular
techniques replaced those of traditional somatic cell genetics.
The total number of mapped X linked loci also rose, from 155
in 1973 to 308 in 1987. The number of mapped genes has
continued to increase rapidly since then, reflecting the
development of new molecular biological techniques and the
institution of the Human Genome Project.
Saturday, April 11, 2009
Human Genome Project
The Human Genome Project was initiated in 1995 as an
international collaborative project with the aim of determining
the DNA sequence of each of the human chromosomes and of
providing unrestricted public access to this information.
Sequencing data have been submitted by 16 collaborating
centres: eight from the United States, three from Germany, two
from Japan and one from France, China, and the UK
respectively. The UK contribution came from the Sanger
Centre at Hinxton in Cambridgeshire, jointly funded by the
Wellcome Trust and the Medical Research Council.
international collaborative project with the aim of determining
the DNA sequence of each of the human chromosomes and of
providing unrestricted public access to this information.
Sequencing data have been submitted by 16 collaborating
centres: eight from the United States, three from Germany, two
from Japan and one from France, China, and the UK
respectively. The UK contribution came from the Sanger
Centre at Hinxton in Cambridgeshire, jointly funded by the
Wellcome Trust and the Medical Research Council.
human genome project
The human genome project consortium used a hierarchical
shotgun approach in which overlapping bacterial clones were
sequenced using mapping data from publicly available maps.
Each bacterial clone was analysed to provide sequence data
with 99.99% accuracy. The first draft of the human sequence
covering 90% of the gene-rich regions of the human genome
was published in a historic article in Nature in February 2001
shotgun approach in which overlapping bacterial clones were
sequenced using mapping data from publicly available maps.
Each bacterial clone was analysed to provide sequence data
with 99.99% accuracy. The first draft of the human sequence
covering 90% of the gene-rich regions of the human genome
was published in a historic article in Nature in February 2001
Gene localisation
Prior to 1980, only a few genes, for disorders whose
biochemical basis was known, had been identified. With the
advent of molecular techniques the first step in isolating many
genes for human diseases was to locate their chromosomal
position by gene mapping studies. In some disorders, such as
Huntington disease, this was achieved by undertaking linkage
studies using polymorphic DNA markers in affected families,
without any prior information about which chromosome
carried the gene. In other disorders, the likely position of the
gene was suggested by identification of a chromosomal
rearrangement in an affected individual in whom it was likely
that one of the chromosomal break points disrupted the gene.
The neurofibromatosis type 1 (NF1) gene, for example, was
isolated after the identification of such a translocation followed
by cloning and sequencing of DNA from the region of the
break point on chromosome 17.
biochemical basis was known, had been identified. With the
advent of molecular techniques the first step in isolating many
genes for human diseases was to locate their chromosomal
position by gene mapping studies. In some disorders, such as
Huntington disease, this was achieved by undertaking linkage
studies using polymorphic DNA markers in affected families,
without any prior information about which chromosome
carried the gene. In other disorders, the likely position of the
gene was suggested by identification of a chromosomal
rearrangement in an affected individual in whom it was likely
that one of the chromosomal break points disrupted the gene.
The neurofibromatosis type 1 (NF1) gene, for example, was
isolated after the identification of such a translocation followed
by cloning and sequencing of DNA from the region of the
break point on chromosome 17.
Duchenne muscular dystrophy
In Duchenne muscular dystrophy, several affected females
had been reported who had one X chromosome disrupted by
an X:autosome translocation with the normal X chromosome
being preferentially inactivated. The site of the break point in
these cases was always on the short arm of the X chromosome
at Xp21, which suggested that this was the location of the gene
for DMD. DNA variations in this region, identified by
hybridisation with DNA probes, provided markers that were
shown to be linked to the gene for DMD in family studies in
1983. Strategies were then developed to identify DNA
sequences from the region of the gene for DMD, some of which
were missing in affected boys indicating that they represented
deleted intragenic sequences. The entire gene for DMD was
subsequently cloned in 1987 and its structure determined.
had been reported who had one X chromosome disrupted by
an X:autosome translocation with the normal X chromosome
being preferentially inactivated. The site of the break point in
these cases was always on the short arm of the X chromosome
at Xp21, which suggested that this was the location of the gene
for DMD. DNA variations in this region, identified by
hybridisation with DNA probes, provided markers that were
shown to be linked to the gene for DMD in family studies in
1983. Strategies were then developed to identify DNA
sequences from the region of the gene for DMD, some of which
were missing in affected boys indicating that they represented
deleted intragenic sequences. The entire gene for DMD was
subsequently cloned in 1987 and its structure determined.
Gene tracking
Once a disease gene has been located using linkage analysis,
DNA markers can be used to track the disease gene through
families to predict the genetic state of individuals at risk. Prior
to identifying specific gene mutations, this can provide
information about carrier risk and enable prenatal diagnosis in
certain situations. Before gene tracking can be used to provide
a predictive test, family members known to be affected or
unaffected must be tested to find an informative DNA marker
within the family and to identify which allele is segregating with
the disease gene in that particular kindred. Because
recombination occurs between homologous chromosomes at
meiosis, a DNA marker that is not very close to a gene on a
particular chromosome will sometimes be inherited
independently of the gene. The closer the marker is to a gene,
the less likely it is that recombination will occur. In practice,
markers that have shown less than 5% recombination with a
disease gene have been useful in detecting carriers and in
prenatal diagnosis, although there is always a margin of error
with this type of test and results are quoted as a probability of
carrying the gene and not as a definitive result. Linkage studies
using intragenic markers provide much more accurate
prediction of genetic state, but this approach is only used now
when mutation analysis is not possible, as in some cases of
Duchenne muscular dystrophy, Marfan syndrome and
neurofibromatosis type 1.
DNA markers can be used to track the disease gene through
families to predict the genetic state of individuals at risk. Prior
to identifying specific gene mutations, this can provide
information about carrier risk and enable prenatal diagnosis in
certain situations. Before gene tracking can be used to provide
a predictive test, family members known to be affected or
unaffected must be tested to find an informative DNA marker
within the family and to identify which allele is segregating with
the disease gene in that particular kindred. Because
recombination occurs between homologous chromosomes at
meiosis, a DNA marker that is not very close to a gene on a
particular chromosome will sometimes be inherited
independently of the gene. The closer the marker is to a gene,
the less likely it is that recombination will occur. In practice,
markers that have shown less than 5% recombination with a
disease gene have been useful in detecting carriers and in
prenatal diagnosis, although there is always a margin of error
with this type of test and results are quoted as a probability of
carrying the gene and not as a definitive result. Linkage studies
using intragenic markers provide much more accurate
prediction of genetic state, but this approach is only used now
when mutation analysis is not possible, as in some cases of
Duchenne muscular dystrophy, Marfan syndrome and
neurofibromatosis type 1.
Gene identification
Once the chromosomal location of a gene has been identified,
there are several strategies that can be employed to isolate the
gene itself. Genes within the region of interest can be searched
for by using techniques such as cDNA selection and screening,
CpG island identification and exon trapping. Any genes
identified can then be studied for mutations in affected
individuals. Alternatively, candidate genes can be identified by
their function or expression patterns or by sequence homology
with genes known to cause similar phenotypes in animals. The
gene for Waardenburg syndrome, for example, was localised to
chromosome 2q by linkage studies and the finding of a
chromosomal abnormality in an affected subject. Identification
of the gene was then aided by recognition of a similar
phenotype in splotch mice. Mutations in the PAX3 gene were
found to underlie the phenotype in both mice and humans.
there are several strategies that can be employed to isolate the
gene itself. Genes within the region of interest can be searched
for by using techniques such as cDNA selection and screening,
CpG island identification and exon trapping. Any genes
identified can then be studied for mutations in affected
individuals. Alternatively, candidate genes can be identified by
their function or expression patterns or by sequence homology
with genes known to cause similar phenotypes in animals. The
gene for Waardenburg syndrome, for example, was localised to
chromosome 2q by linkage studies and the finding of a
chromosomal abnormality in an affected subject. Identification
of the gene was then aided by recognition of a similar
phenotype in splotch mice. Mutations in the PAX3 gene were
found to underlie the phenotype in both mice and humans.
Subscribe to:
Comments (Atom)
